Vaccine and wild-type strains of yellow fever virus engage distinct entry mechanisms and differentially stimulate antiviral immune responses

mBio

Volumn 7, Issue 1, 2016, Pages

  Fernandez Garcia, Maria Dolores ^a,b,c,g   Meertens, Laurent ^a,b,c   Chazal, Maxime ^d   Hafirassou, Mohamed Lamine ^a,b,c   Dejarnac, Ophélie ^a,b,c   Zamborlini, Alessia ^a,b,c,e   Despres, Philippe ^f   Sauvonnet, Nathalie ^d   Arenzana Seisdedos, Fernando ^d   Jouvenet, Nolwenn ^d   Amara, Ali ^a,b,c  

^a Institut Universitaire d'Hématologie   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSTITUT PASTEUR   (France)

^e University of Paris Cité   (France)

^f UNIVERSITÉ DE LA RÉUNION   (France)

^g INSTITUT PASTEUR DE DAKAR   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

17D E PROTEIN; 17D VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS RNA; VIRUS VACCINE; YELLOW FEVER VACCINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RESPONSE; ENDOCYTOSIS; ENDOSOME; GENE MUTATION; HOST CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFECTION RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION; TARGET CELL; VIRUS ENTRY; WILD TYPE; YELLOW FEVER VIRUS; CELL LINE; IMMUNOLOGY; INNATE IMMUNITY; PHYSIOLOGY;

CELL LINE; ENDOCYTOSIS; HUMANS; IMMUNITY, INNATE; VIRUS INTERNALIZATION; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84960145753     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01956-15     Document Type: Article

References (71)

1. Fernandez-Garcia MD, Mazzon M, Jacobs M, Amara A. 2009. Pathogenesis of flavivirus infections: using and abusing the host cell. Cell Host Microbe 5:318–328. http://dx.doi.org/10.1016/j.chom.2009.04.001.
2. Lindenbach BD, Rice CM. 2003. Molecular biology of flaviviruses. Adv Virus Res 59:23–61. http://dx.doi.org/10.1016/S0065-3527(03)59002-9.
3. Monath TP, Barrett AD. 2003. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res 60:343–395. http://dx.doi.org/10.1016/S0065-3527(03)60009-6.
4. Pulendran B. 2009. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 9:741–747. http://dx.doi.org/10.1038/nri2629.
5. Barrett AD, Teuwen DE. 2009. Yellow fever vaccine—how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol 21:308–313. http://dx.doi.org/10.1016/j.coi.2009.05.018.
6. Monath TP. 2005. Yellow fever vaccine. Expert Rev Vaccines 4:553–574. http://dx.doi.org/10.1586/14760584.4.4.553.
7. Pulendran B, Oh JZ, Nakaya HI, Ravindran R, Kazmin DA. 2013. Immunity to viruses: learning from successful human vaccines. Immunol Rev 255:243–255. http://dx.doi.org/10.1111/imr.12099.
8. Hahn CS, Dalrymple JM, Strauss JH, Rice CM. 1987. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad SciUSA84:2019–2023. http://dx.doi.org/10.1073/pnas.84.7.2019.
9. Barrett AD, Monath TP, Cropp CB, Adkins JA, Ledger TN, Gould EA, Schlesinger JJ, Kinney RM, Trent DW. 1990. Attenuation of wild-type yellow fever virus by passage in HeLa cells. J Gen Virol 71:2301–2306. http://dx.doi.org/10.1099/0022-1317-71-10-2301.
10. Sil BK, Dunster LM, Ledger TN, Wills MR, Minor PD, Barrett AD. 1992. Identification of envelope protein epitopes that are important in the attenuation process of wild-type yellow fever virus. J Virol 66:4265–4270.
11. Lee E, Lobigs M. 2008. E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J Virol 82:6024–6033. http://dx.doi.org/10.1128/JVI.02509-07.
12. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, Kennedy K, Wu H, Bennouna S, Oluoch H, Miller J, Vencio RZ, Mulligan M, Aderem A, Ahmed R, Pulendran B. 2009. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10:116–125. http://dx.doi.org/10.1038/ni.1688.
13. Wheelock EF, Sibley WA. 1965. Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow-fever virus. N Engl J Med 273:194–198. http://dx.doi.org/10.1056/NEJM196507222730404.
14. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, Moser JM, Mehta RS, Drake DR, III, Castro E, Akondy R, Rinfret A, Yassine-Diab B, Said EA, Chouikh Y, Cameron MJ, Clum R, Kelvin D, Somogyi R, Greller LD, Balderas RS, Wilkinson P, Pantaleo G, Tartaglia J, Haddad EK, Sekaly RP. 2008. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205:3119–3131. http://dx.doi.org/10.1084/jem.20082292.
15. Lefeuvre A, Contamin H, Decelle T, Fournier C, Lang J, Deubel V, Marianneau P. 2006. Host-cell interaction of attenuated and wild-type strains of yellow fever virus can be differentiated at early stages of hepatocyte infection. Microbes Infect 8:1530–1538. http://dx.doi.org/10.1016/j.micinf.2006.01.013.
16. Smit JM, Moesker B, Rodenhuis-Zybert I, Wilschut J. 2011. Flavivirus cell entry and membrane fusion. Viruses 3:160–171. http://dx.doi.org/10.3390/v3020160.
17. McMahon HT, Boucrot E. 2011. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 12: 517–533. http://dx.doi.org/10.1038/nrm3151.
18. Krishnan MN, Sukumaran B, Pal U, Agaisse H, Murray JL, Hodge TW, Fikrig E. 2007. Rab 5 is required for the cellular entry of dengue and West Nile viruses. J Virol 81:4881–4885. http://dx.doi.org/10.1128/JVI.02210-06.
19. Chu JJ, Ng ML. 2004. Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway. J Virol 78:10543–10555. http://dx.doi.org/10.1128/JVI.78.19.10543-10555.2004.
20. Benmerah A, Bayrou M, Cerf-Bensussan N, Dautry-Varsat A. 1999. Inhibition of clathrin-coated pit assembly by an Eps15 mutant. J Cell Sci 112:1303–1311.
21. Mayor S, Pagano RE. 2007. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 8:603–612. http://dx.doi.org/10.1038/nrm2216.
22. Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. 2006. Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell 10: 839–850. http://dx.doi.org/10.1016/j.devcel.2006.04.002.
23. Damke H, Baba T, Warnock DE, Schmid SL. 1994. Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J Cell Biol 127:915–934. http://dx.doi.org/10.1083/jcb.127.4.915.
24. Mayor S, Parton RG, Donaldson JG. 2014. Clathrin-independent pathways of endocytosis. Cold Spring Harb Perspect Biol 6:a016758. http://dx.doi.org/10.1101/cshperspect.a016758.
25. Stenmark H. 2009. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol 10:513–525. http://dx.doi.org/10.1038/nrm2728.
26. Sieczkarski SB, Whittaker GR. 2003. Differential requirements of Rab5 and Rab7 for endocytosis of influenza and other enveloped viruses. Traffic 4:333–343. http://dx.doi.org/10.1034/j.1600-0854.2003.00090.x.
27. Pierson TC, Sánchez MD, Puffer BA, Ahmed AA, Geiss BJ, Valentine LE, Altamura LA, Diamond MS, Doms RW. 2006. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346:53–65. http://dx.doi.org/10.1016/j.virol.2005.10.030.
28. Hoffmann HH, Schneider WM, Rice CM. 2015. Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol 36:124–138. http://dx.doi.org/10.1016/j.it.2015.01.004.
29. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481–485. http://dx.doi.org/10.1038/nature09907.
30. Melchjorsen J, Sørensen LN, Paludan SR. 2003. Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo function. J Leukoc Biol 74:331–343. http://dx.doi.org/10.1189/jlb.1102577.
31. Sieczkarski SB, Whittaker GR. 2002. Influenza virus can enter and infect cells in the absence of clathrin-mediated endocytosis. J Virol 76: 10455–10464. http://dx.doi.org/10.1128/JVI.76.20.10455-10464.2002.
32. Sanchez-San Martin C, López T, Arias CF, López S. 2004. Characterization of rotavirus cell entry. J Virol 78:2310–2318. http://dx.doi.org/10.1128/JVI.78.5.2310-2318.2004.
33. Khan AG, Pickl-Herk A, Gajdzik L, Marlovits TC, Fuchs R, Blaas D. 2010. Human rhinovirus 14 enters rhabdomyosarcoma cells expressing ICAM-1 by a clathrin-, caveolin-, and flotillin-independent pathway. J Virol 84:3984–3992. http://dx.doi.org/10.1128/JVI.01693-09.
34. Acosta EG, Castilla V, Damonte EB. 2009. Alternative infectious entry pathways for dengue virus serotypes into mammalian cells. Cell Microbiol 11:1533–1549. http://dx.doi.org/10.1111/j.1462-5822.2009.01345.x.
35. Kalia M, Khasa R, Sharma M, Nain M, Vrati S. 2013. Japanese encephalitis virus infects neuronal cells through a clathrin-independent endocytic mechanism. J Virol 87:148–162. http://dx.doi.org/10.1128/JVI.01399-12.
36. Grassart A, Dujeancourt A, Lazarow PB, Dautry-Varsat A, Sauvonnet N. 2008. Clathrin-independent endocytosis used by the IL-2 receptor is regulated by Rac1, Pak1 and Pak2. EMBO Rep 9:356–362. http://dx.doi.org/10.1038/embor.2008.28.
37. Basquin C, Malardé V, Mellor P, Anderson DH, Meas-Yedid V, Olivo-Marin JC, Dautry-Varsat A, Sauvonnet N. 2013. The signalling factor PI3K is a specific regulator of the clathrin-independent dynamindependent endocytosis of IL-2 receptors. J Cell Sci 126:1099–1108. http://dx.doi.org/10.1242/jcs.110932.
38. Yanagi Y, Takeda M, Ohno S, Hashiguchi T. 2009. Measles virus receptors. Curr Top Microbiol Immunol 329:13–30.
39. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. 2000. Ligand binding to integrins. J Biol Chem 275:21785–21788. http://dx.doi.org/10.1074/jbc.R000003200.
40. Lepiniec L, Dalgarno L, Huong VT, Monath TP, Digoutte JP, Deubel V. 1994. Geographic distribution and evolution of yellow fever viruses based on direct sequencing of genomic cDNA fragments. J Gen Virol 75: 417–423. http://dx.doi.org/10.1099/0022-1317-75-2-417.
41. Barba-Spaeth G, Longman RS, Albert ML, Rice CM. 2005. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 202:1179–1184. http://dx.doi.org/10.1084/jem.20051352.
42. van der Most RG, Corver J, Strauss JH. 1999. Mutagenesis of the RGD motif in the yellow fever virus 17D envelope protein. Virology 265:83–95. http://dx.doi.org/10.1006/viro.1999.0026.
43. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E. 2002. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology 292:162–168. http://dx.doi.org/10.1006/viro.2001.1232.
44. Nickells J, Cannella M, Droll DA, Liang Y, Wold WS, Chambers TJ. 2008. Neuroadapted yellow fever virus strain 17D: a charged locus in domain III of the E protein governs heparin binding activity and neuroinvasiveness in the SCID mouse model. J Virol 82:12510–12519. http://dx.doi.org/10.1128/JVI.00458-08.
45. Lee E, Hall RA, Lobigs M. 2004. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J Virol 78:8271–8280. http://dx.doi.org/10.1128/JVI.78.15.8271-8280.2004.
46. Lee E, Lobigs M. 2002. Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. J Virol 76:4901–4911. http://dx.doi.org/10.1128/JVI.76.10.4901-4911.2002.
47. Lee E, Lobigs M. 2000. Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry. J Virol 74:8867–8875. http://dx.doi.org/10.1128/JVI.74.19.8867-8875.2000.
48. Lee E, Wright PJ, Davidson A, Lobigs M. 2006. Virulence attenuation of dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. J Gen Virol 87:2791–2801. http://dx.doi.org/10.1099/vir.0.82164-0.
49. Mandl CW, Kroschewski H, Allison SL, Kofler R, Holzmann H, Meixner T, Heinz FX. 2001. Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo. J Virol 75:5627–5637. http://dx.doi.org/10.1128/JVI.75.12.5627-5637.2001.
50. Bernard KA, Klimstra WB, Johnston RE. 2000. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276:93–103. http://dx.doi.org/10.1006/viro.2000.0546.
51. Byrnes AP, Griffin DE. 1998. Binding of Sindbis virus to cell surface heparan sulfate. J Virol 72:7349–7356.
52. Sa-Carvalho D, Rieder E, Baxt B, Rodarte R, Tanuri A, Mason PW. 1997. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol 71: 5115–5123.
53. Payne CK, Jones SA, Chen C, Zhuang X. 2007. Internalization and trafficking of cell surface proteoglycans and proteoglycan-binding ligands. Traffic 8:389–401. http://dx.doi.org/10.1111/j.1600-0854.2007.00540.x.
54. Bruni D, Chazal M, Sinigaglia L, Chauveau L, Schwartz O, Desprès P, Jouvenet N. 2015. Viral entry route determines how human plasmacytoid dendritic cells produce type I interferons. Sci Signal 8:ra25. http://dx.doi.org/10.1126/scisignal.aaa1552.
55. Mandl JN, Akondy R, Lawson B, Kozyr N, Staprans SI, Ahmed R, Feinberg MB. 2011. Distinctive TLR7 signaling, type I IFN production, and attenuated innate and adaptive immune responses to yellow fever virus in a primate reservoir host. J Immunol 186:6406–6416. http://dx.doi.org/10.4049/jimmunol.1001191.
56. Ye J, Zhu B, Fu ZF, Chen H, Cao S. 2013. Immune evasion strategies of flaviviruses. Vaccine 31:461–471. http://dx.doi.org/10.1016/j.vaccine.2012.11.015.
57. Beck A, Tesh RB, Wood TG, Widen SG, Ryman KD, Barrett AD. 2014. Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing. J Infect Dis 209: 334–344. http://dx.doi.org/10.1093/infdis/jit546.
58. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. 2006. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439:344–348. http://dx.doi.org/10.1038/nature04388.
59. Lozach PY, Amara A, Bartosch B, Virelizier JL, Arenzana-Seisdedos F, Cosset FL, Altmeyer R. 2004. C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem 279:32035–32045.
60. Rice CM, Grakoui A, Galler R, Chambers TJ. 1989. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol 1:285–296.
61. Pierson TC, Diamond MS, Ahmed AA, Valentine LE, Davis CW, Samuel MA, Hanna SL, Puffer BA, Doms RW. 2005. An infectious West Nile virus that expresses a GFP reporter gene. Virology 334:28–40. http://dx.doi.org/10.1016/j.virol.2005.01.021.
62. Hayer A, Stoeber M, Bissig C, Helenius A. 2010. Biogenesis of caveolae: stepwise assembly of large caveolin and cavin complexes. Traffic 11: 361–382. http://dx.doi.org/10.1111/j.1600-0854.2009.01023.x.
63. Meertens L, Bertaux C, Dragic T. 2006. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol 80:11571–11578. http://dx.doi.org/10.1128/JVI.01717-06.
64. Subtil A, Hémar A, Dautry-Varsat A. 1994. Rapid endocytosis of interleukin 2 receptors when clathrin-coated pit endocytosis is inhibited. J Cell Sci 107:3461–3468. http://dx.doi.org/10.1016/0248-4900(96)81369-4.
65. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM, Ebel GD, Kramer LD, Fremont DH, Diamond MS. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11:522–530. http://dx.doi.org/10.1038/nm1240.
66. Brault JB, Kudelko M, Vidalain PO, Tangy F, Desprès P, Pardigon N. 2011. The interaction of flavivirus M protein with light chain Tctex-1 of human dynein plays a role in late stages of virus replication. Virology 417:369–378. http://dx.doi.org/10.1016/j.virol.2011.06.022.
67. Snijder B, Sacher R, Rämö P, Liberali P, Mench K, Wolfrum N, Burleigh L, Scott CC, Verheije MH, Mercer J, Moese S, Heger T, Theusner K, Jurgeit A, Lamparter D, Balistreri G, Schelhaas M, De Haan CA, Marjomäki V, Hyypiä T, Rottier PJ, Sodeik B, Marsh M, Gruenberg J, Amara A, Greber U, Helenius A, Pelkmans L. 2012. Single-cell analysis of population context advances RNAi screening at multiple levels. Mol Syst Biol 8:579. http://dx.doi.org/10.1038/msb.2012.9.
68. Lozach PY, Burleigh L, Staropoli I, Navarro-Sanchez E, Harriague J, Virelizier JL, Rey FA, Desprès P, Arenzana-Seisdedos F, Amara A. 2005. Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J Biol Chem 280: 23698–23708. http://dx.doi.org/10.1074/jbc.M504337200.
69. Meertens L, Carnec X, Lecoin MP, Ramdasi R, Guivel-Benhassine F, Lew E, Lemke G, Schwartz O, Amara A. 2012. The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe 12:544–557. http://dx.doi.org/10.1016/j.chom.2012.08.009.
70. Grassart A, Meas-Yedid V, Dufour A, Olivo-Marin JC, Dautry-Varsat A, Sauvonnet N. 2010. Pak1 phosphorylation enhances cortactin-NWASP interaction in clathrin-caveolin-independent endocytosis. Traffic 11:1079–1091. http://dx.doi.org/10.1111/j.1600-0854.2010.01075.x.
71. Basquin C, Malardé V, Mellor P, Anderson DH, Meas-Yedid V, Olivo-Marin JC, Dautry-Varsat A, Sauvonnet N. 2013. The signalling factor PI 3-kinase is a specific regulator of the clathrin-independent dynamindependent endocytosis of IL-2 receptors. J Cell Sci 126:1099–1108. http://dx.doi.org/10.1242/jcs.110932.